Page last updated: 2024-09-04

edotreotide and yttrium

edotreotide has been researched along with yttrium in 3 studies

Compound Research Comparison

Studies
(edotreotide)
Trials
(edotreotide)
Recent Studies (post-2010)
(edotreotide)
Studies
(yttrium)
Trials
(yttrium)
Recent Studies (post-2010) (yttrium)
20634863,3851661,626

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Valkema, R1
Deshmukh, MV; Gemmecker, G; Kessler, H; Kühlewein, A; Mäcke, H; Schmitt, J; Voll, G1
Angelini, C; Caprotti, R; Crippa, S; Mussi, C; Sartori, P; Uggeri, F1

Other Studies

3 other study(ies) available for edotreotide and yttrium

ArticleYear
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46 Suppl 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Humans; Lutetium; Male; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Somatostatin; Survival Analysis; Treatment Outcome; Yttrium

2005
NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide.
    Journal of medicinal chemistry, 2005, Mar-10, Volume: 48, Issue:5

    Topics: Gallium; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Structure; Octreotide; Organometallic Compounds; Stereoisomerism; Yttrium

2005
Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.
    Langenbeck's archives of surgery, 2005, Volume: 390, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Octreotide; Palliative Care; Radiopharmaceuticals; Yttrium

2005